drugset

drugset / Trial / NCT06395753

A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer

NCT06395753 ↗

Phase 2 Active not recruiting 55 enrolled Debiopharm International SA

RandomizedParallel-groupOpen-labelTreatment

Summary

The primary purpose of this study is to determine the pharmacokinetics (PK) and pharmacodynamics (PD) of Debio 4228.

Timeline

Start: 2024-05-23
Primary completion: 2026-06
Completion: 2026-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Debio 4228	Unknown	—	Intramuscular

Indications